


ABSTRACT OF THE DISCLOSURE

The present invention is directed to 5-HT₂ receptor antagonist compounds of formula I:

5



10

15 in which

the dashed line denotes an optional double bond;

n is 1, 2 or 3;

p is 0, 1, 2 or 3;

q is 0, 1 or 2;





20 each R¹ is independently selected from halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, amino carbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino;

each R² is lower alkyl; and

25

BEST AVAILABLE COPY

R^3 is a group selected from Formulae (a), (b), (c) and (d):



in which

u is 0 or 1;

z is 1, 2 or 3; and

R^4 is C_{1-7} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-2} alkyl, or a group $(CH_2)_t R^5$ where t is 1 or 2 and R^5 is thienyl, pyrrolyl, or furyl, each optionally further substituted

by one or two substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, trifluoromethyl or halogen, or is phenyl

optionally substituted by one or two substituents

selected from C_{1-4} alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C_{1-4} alkyl

optionally substituted by hydroxy, C_{1-4} alkoxy, carboxy, esterified carboxy or *in vivo* hydrolyzable acyloxy; and the pharmaceutically acceptable salts, individual

isomers, mixtures of isomers, processes for preparation, compositions, and methods of use thereof.

BEST AVAILABLE COPY